

**4th International ALL Assembly  
17–18 January 2020  
Radisson Blu Hotel, Frankfurt, Germany**

**Agenda outline**

**Co-chairs: Nicola Gökbuget (GER) and Josep Ribera (ESP) TBC**

<b>Friday</b>		
<b>Time</b>	<b>Session</b>	<b>Speaker/Chair</b>
12.00–13.00	Lunch	
13.00–13.10	Welcome and introduction	Nicola Gökbuget (GER)
<b>Session 1</b>	<b>Frontline therapy of ALL</b>	<b>Herve Dombret (FRA)</b>
13.10–13.30	<i>Latest concepts in frontline therapy for paediatric ALL</i>	Ching-Hon Pui (USA)
13.30–13.50	<i>Treatment of Ph-negative ALL in adolescents and young adults</i>	Josep Ribera (ESP)
13.50–14.10	<i>Therapy of Ph-positive adult ALL</i>	Oliver Ottmann (UK)
14.10–14.30	Panel discussion	All
<b>Session 2</b>	<b>Post-remission therapy of ALL</b>	<b>Franco Locatelli (ITA)</b>
14.30–14.50	<i>Management of minimal residual disease</i>	Renato Bassan (ITA)
14.50–15.10	<i>Donor selection in HSCT</i>	Sebastian Giebel (POL)
15.10–15.30	<i>Long-term toxicities in paediatric ALL</i>	Kjeld Schmiegelow (DEN)
15.30–15.50	Panel discussion	All
15.50–16.20	Coffee break	
<b>16.20–18.00</b>	<b>Move to workshop rooms 7 interactive case study workshops, 2 x 45 min with 10 min break for rotations</b>	
	<i>Safety considerations for patients receiving BiTE® immuno-oncology therapy</i>	Max Topp (GER)
	<i>Innovative immunotherapy approaches for paediatric ALL</i>	Rupert Handgretinger (GER)
	<i>Management of asparaginase safety profile</i>	Carmelo Rizzari (ITA)
	<i>Safety considerations for inotuzumab in the setting of HSCT</i>	TBC
	<i>Atypical origin of ALL</i>	Josep Ribera (ESP)
	<i>Management of infectious complications</i>	TBC
	<i>Clinical heterogeneity of ALL patients: how to consider for treatment decisions</i>	Nicola Gökbuget (GER)
<b>18.00</b>	<b>Informal meet the expert session</b>	
19.00	Dinner	

Saturday		
Time	Session	Speaker/Chair
09.00–09.05	Welcome and introduction to Day 2	Josep Ribera (ESP)
<b>Session 3</b>	<b>Interactive debate</b>	<b>TBC</b>
9.05–10.05	BiTE <sup>®</sup> therapy followed by HSCT vs CAR-T cells in young patients with relapsed/refractory ALL	Franco Locatelli (ITA) Peter Bader (GER)
	Panel discussion	All
<b>10.05–10.50</b>	<b>7 special interest workshops (45 mins)</b>	
	<i>Treatment of older and less fit patients with ALL</i>	Adele Fielding (UK)
	<i>Modern therapy of T-ALL</i>	Nicolas Boissel (FRA)
	<i>CAR-T cells: future approaches and next-generation constructs</i>	Sara Ghorashian (UK)
	<i>Management of CRS in patients treated with CD19-targeted immuno-oncology therapies</i>	Peter Bader (GER)
	<i>Patient QoL in adult ALL</i>	Zack Pemberton-Whitely (UK)
	<i>Value-based review of novel therapies</i>	Hervé Dombret (FRA)
	<i>MRD assessment for ALL in the era of targeted treatment</i>	Monika Brüggemann (GER)
	<i>Hereditary basis of ALL</i>	Christian Kratz (GER)
10.50–11.20	Coffee break	
<b>Session 4</b>	<b>Management of relapsed/refractory B-ALL</b>	<b>Nicola Gökbüget (GER)</b>
11.20–11.40	<i>Chemotherapy/ADCs</i>	Max Topp (GER)
11.40–12.00	<i>BiTE<sup>®</sup> immuno-oncology therapy</i>	Nicolas Boissel (FRA)
12.00–12.20	<i>Adoptive cell therapies for B-ALL</i>	Rupert Handgretinger (GER)
12.20–12.40	<i>Considerations for treatment sequencing in B-ALL</i>	Nicola Gökbüget (GER)
12.40–13.00	Panel discussion	All
13.00–14.00	Lunch	
<b>Session 5</b>	<b>Latest concepts in ALL biology and genetics</b>	<b>Renato Bassan (ITA)</b>
14.00–14.20	<i>The ALL microenvironment</i>	Charles Mullighan (USA)
14.20–14.40	<i>New genetic subtypes of adult ALL</i>	Emmanuelle Clappier (FRA)
14.40–15.00	<i>Identifying poor-prognosis subgroups of paediatric ALL</i>	Ching-Hon Pui (USA)
15.00–15.20	Panel discussion	All
15.20–15.35	<i>Future horizons in paediatric ALL</i>	Franco Locatelli (ITA)
15.35–15.40	Meeting close	Josep Ribera (ESP)